Why the study?
Desmodium gyrans DC has been used in traditional medicine as a cardiotonic, but scientific literature supporting its medicinal use was lacking.
Does methanolic extract of Desmodium gyrans DC protect against doxorubicin-induced cardiomyopathy and isoproterenol-induced myocardial infarction in rats?
Does methanolic extract of Desmodium gyrans DC protect against doxorubicin-induced cardiomyopathy and isoproterenol-induced myocardial infarction in rats?
Methanolic extract of Desmodium gyrans DC demonstrates cardioprotective effects against isoproterenol-induced myocardial infarction and doxorubicin-induced cardiomyopathy in rats by restoring redox balance.
Hypothesis-generating in rat models; leaves open translation to human cardioprotection.
Desmodium gyrans DC (Fabaceae) has been widely used in Indian and Chinese traditional medicine as a cardiotonic and for wound healing. There is not much scientific literature supporting the medicinal use of the plant. The present study aimed to evaluate the cardioprotective effect of the methanolic extract of D. gyrans in rats. The objective of the study is to validate the use of the plant in traditional medicine. The cardioprotective effect of this plant was studied in Sprague Dawley rats by separately inducing cardiomyopathy and myocardial infarction using doxorubicin (DOX) and isoproterenol (ISO), respectively. Variations in serum cardiac markers, antioxidants, and lipid peroxidation levels in cardiac tissue were analyzed. Antioxidant status was also studied in the cardiac mitochondrial fraction. A histopathological examination of heart tissue was done. The results indicated a significant increase in the lipid peroxidation products with a concomitant reduction in the tissue antioxidant enzymes activities (SOD and GPx) and glutathione levels in DOX and ISO alone treated rats. However, treatment of the rats with D. gyrans restored the redox balance in the cardiac tissues of these rats. Overall, the results showed that the methanolic extract of D. gyrans has significant protective activity against ISO-induced myocardial infarction and moderate protection against DOX-induced cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Sivaram et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: